Free Trial
NASDAQ:BNTX

BioNTech (BNTX) Stock Price, News & Analysis

BioNTech logo
$120.01 +2.13 (+1.81%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$122.39 +2.38 (+1.98%)
As of 02/21/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About BioNTech Stock (NASDAQ:BNTX)

Key Stats

Today's Range
$116.50
$123.87
50-Day Range
$111.34
$126.88
52-Week Range
$76.53
$131.49
Volume
1.36 million shs
Average Volume
667,508 shs
Market Capitalization
$28.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$142.72
Consensus Rating
Moderate Buy

Company Overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

BioNTech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

BNTX MarketRank™: 

BioNTech scored higher than 48% of companies evaluated by MarketBeat, and ranked 602nd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 13 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioNTech has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BioNTech's stock forecast and price target.
  • Earnings Growth

    Earnings for BioNTech are expected to decrease in the coming year, from ($3.88) to ($4.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioNTech is -57.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioNTech is -57.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioNTech has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about BioNTech's valuation and earnings.
  • Percentage of Shares Shorted

    1.14% of the outstanding shares of BioNTech have been sold short.
  • Short Interest Ratio / Days to Cover

    BioNTech has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioNTech has recently increased by 3.79%, indicating that investor sentiment is decreasing.
  • Percentage of Shares Shorted

    1.14% of the outstanding shares of BioNTech have been sold short.
  • Short Interest Ratio / Days to Cover

    BioNTech has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioNTech has recently increased by 3.79%, indicating that investor sentiment is decreasing.
  • News Sentiment

    BioNTech has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for BioNTech this week, compared to 11 articles on an average week.
  • Search Interest

    27 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 4% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioNTech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 15.52% of the stock of BioNTech is held by institutions.

  • Read more about BioNTech's insider trading history.
Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

BNTX Stock News Headlines

Senate votes to confirm Robert Kennedy as head of HHS
Ex-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”
Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. Should you sit on the sideline while this is happening?
BioNTech price target lowered to $147 from $150 at BofA
See More Headlines

BNTX Stock Analysis - Frequently Asked Questions

BioNTech's stock was trading at $113.95 on January 1st, 2025. Since then, BNTX shares have increased by 5.3% and is now trading at $120.01.
View the best growth stocks for 2025 here
.

BioNTech SE (NASDAQ:BNTX) issued its quarterly earnings results on Monday, November, 4th. The company reported $0.81 EPS for the quarter, beating analysts' consensus estimates of ($1.26) by $2.07. The company's revenue was up 38.9% on a year-over-year basis.

BioNTech subsidiaries include Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and others.

BioNTech (BNTX) raised $251 million in an IPO on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

BioNTech's top institutional shareholders include Baillie Gifford & Co. (3.43%), FMR LLC (3.21%), Flossbach Von Storch SE (1.84%) and Primecap Management Co. CA (1.79%).

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
11/04/2024
Today
2/21/2025
Next Earnings (Estimated)
3/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BNTX
Employees
6,133
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$142.72
High Stock Price Target
$172.00
Low Stock Price Target
$122.00
Potential Upside/Downside
+18.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
17 Analysts

Profitability

Net Income
$1.01 billion
Pretax Margin
-9.91%

Debt

Sales & Book Value

Annual Sales
$3.04 billion
Cash Flow
$5.09 per share
Book Value
$92.17 per share

Miscellaneous

Free Float
193,710,000
Market Cap
$28.77 billion
Optionable
Optionable
Beta
0.17

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:BNTX) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners